Video Experimental Relacionado
Updated: Jul 18, 2026
08:35
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Nuevos objetivos farmacológicos para la diabetes tipo 2 y el síndrome metabólico
1Departments of Molecular Endocrinology and Metabolic Disorders, Merck Research Laboratories, Rahway, New Jersey 07065, USA.
Nature
|December 14, 2001
Resumen
El aumento global de las características del síndrome metabólico alimenta una epidemia de diabetes tipo 2. Las nuevas terapias se dirigen a mecanismos clave como el deterioro de la secreción de insulina y la lipotoxicidad, ofreciendo esperanzas de tratamientos efectivos.
Área de la Ciencia:
- Endocrinología y Metabolismo.
- La medicina molecular es una medicina molecular.
- Farmacología Farmacología.
Sus antecedentes:
- El síndrome metabólico, caracterizado por la obesidad, la resistencia a la insulina y la dislipidemia, está impulsando una epidemia mundial de diabetes mellitus tipo 2.
- Los tratamientos actuales para la diabetes tipo 2 a menudo carecen de objetivos moleculares específicos debido a una comprensión incompleta de la patogénesis de la enfermedad.
Objetivo del estudio:
- Para resaltar los nuevos objetivos farmacológicos moleculares emergentes para la diabetes tipo 2.
- Discutir nuevas estrategias terapéuticas basadas en los avances recientes en la comprensión de los mecanismos de la enfermedad.
Principales métodos:
- Revisión de los conocimientos actuales sobre el síndrome metabólico y la patogénesis de la diabetes tipo 2.
- Identificación y discusión de objetivos moleculares clave implicados en la progresión de la enfermedad.
- Validación de objetivos a través de la ingeniería genética en modelos animales y estudios preliminares en humanos y animales.
Principales resultados:
- Investigaciones emergentes identifican el deterioro de la secreción de insulina estimulada por la glucosa como un factor crítico.
- La lipotoxicidad es reconocida como un contribuyente significativo a la resistencia hepática y muscular a la insulina.
- Se han identificado y validado varios nuevos objetivos moleculares en entornos preclínicos y clínicos tempranos.
Conclusiones:
- Comprender las bases moleculares de la resistencia a la insulina y el deterioro de la secreción de insulina es crucial para desarrollar terapias efectivas para la diabetes tipo 2.
- Los nuevos objetivos farmacológicos informados por la lipotoxicidad y los mecanismos de secreción de insulina son prometedores.
- Las terapias dirigidas representan un avance significativo en el manejo del síndrome metabólico y la epidemia de diabetes tipo 2.
Videos de Conceptos Relacionados
01:17Oral Hypoglycemic Agents: Sulfonylureas
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...